Bringing pharmaceutical industry expertise to the world of medicinal cannabis

Investor Roadshow Australia
March 2017
Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso. This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient’s should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1933 (Securities Act). The Company’s shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.
Industry in Flux

- The medicinal cannabis industry is still in its infancy and dominated by small players with no pharmaceutical industry expertise.
- This has led to questionable treatments due to the lack of standardisation in formulation and dosage of cannabis derived products.
- There is a remarkable lack of trusted cannabis brands in the global marketplace.
- Established pharmaceutical companies are generally reluctant to enter the market due to evolving regulations.

*Creso brings pharmaceutical industry expertise and rigor to the world of medicinal cannabis*
Company Summary

ASX: CPH
Headquarters in Zug, Switzerland

Bringing pharmaceutical industry expertise to the world of medicinal cannabis

- Creso Pharma’s operational HQ is in Zug, Switzerland
- Best-in-class with highest Good Manufacturing Practice (GMP) certified processes
- Standardised cannabis-based treatments that meet international pharmaceutical standards
- Exclusive technology for more effective delivery of dosage
- Focus on the nutraceutical (food supplement) market for both humans and pets

<table>
<thead>
<tr>
<th></th>
<th>$m</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Cap @ 54 cents*</td>
<td>22.8</td>
<td></td>
</tr>
<tr>
<td>Cash at Hand</td>
<td>3.1</td>
<td></td>
</tr>
<tr>
<td>Enterprise value</td>
<td>19.7</td>
<td></td>
</tr>
<tr>
<td>Shares on Issue</td>
<td>42.1m</td>
<td></td>
</tr>
<tr>
<td>Top 20 shareholders</td>
<td>64.04%</td>
<td></td>
</tr>
<tr>
<td>Escrowed Shares</td>
<td>15.6m (37% of Shares On Issue)</td>
<td></td>
</tr>
</tbody>
</table>

*Data as at March 9, 2017
Creso Pharma Switzerland GmbH with its registered office in Zug (Creso Switzerland) has been incorporated as a Swiss-based wholly owned subsidiary. Creso Pharma Switzerland is used as the legal entity to run the Company’s operations and activities, specifically those situated in Europe being the development and commercialization of its therapeutic products.
Achievements since IPO

- **LOI with Streuli Pharma for the commercialisation of Creso’s products based on the INNutri Soft Gums™ technology in the Swiss market**

- **Binding LOI to develop and commercialise Creso’s innovative cannabidiol (CBD)-rich hemp-derived nutraceutical products for the global pet care market**

- **December 2016: Hemp-Industries fulfils second shipment of hemp protein to one of the Slovakia’s largest bakeries**

- **Australian LOI with pharmaceutical group Health House International Pty Ltd relating to the import and sale of Canadian cannabis products in the Australian market**

- **Prof. Dr. med Felix Gutzwiller appointed to Creso’s Scientific Advisory Board**

- **Oct 2016:** First distribution agreement to sell CBDium, initially in the Czech Republic

- **Nov 2016:** Marketing LOI with Canada’s CanniMed for EU market

- **Dec 2016:** Creso Pharma and Greveling Holding BV are the first companies globally to be awarded European Union (EU) registration for two cannabidiol (CBD)-based proprietary formulation animal feed nutraceutical products

- **Feb 2017:** Health House International granted a federal import licence following the Federal Government’s authorisation of the importation of medical cannabis from international sources

- **Mar 2017:** Creso broadens product pipeline through binding LOI with Domaco to develop and commercialise two new human and one new animal health nutraceutical products
Investment Proposition

- **Fills void in current market with growing need for trusted products that meet the highest global pharmaceutical standards**

- **Revenue generating via its subsidiary, Hemp-Industries**

- **Growing market opportunity with six products in pipeline targeting human and animal nutraceutical markets**

- **Exclusive licensing deals that gives Creso access to unique drug delivery IP**

- **Diversified revenue stream targeting human and pet health markets**

- **Large global market that is only at the start of its growth**

- **Company well placed to be the “gold standard” in trusted cannabis treatments**
Board of Directors

Dr. Miri Halperin Wernli
CEO & Co-Founder

Dr. Halperin Wernli is a senior pharma executive with over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.

Boaz Wachtel
Chairman & Co-Founder

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia’s first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.

Dr. Simon Buckingham
Non-Executive Director

Dr. Buckingham is a company director and adviser with over 25 years’ senior executive experience in top tier global pharmaceutical/ biotechnology companies. His experience covers a wide range of therapeutic areas and spans general management, sales, marketing, clinical development, business development, M&A and corporate strategic planning. He is a veterinarian by training and holds a PhD from the University of Melbourne.

Adam Blumenthal
Non-Executive Director & Co-Founder

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.

Dr. James Ellingford
Non-Executive Director

Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
Advisory Board

Dr. Isaac Kobrin
Industry Advisor

Dr. Stéphane Redey
Industry Advisor

Dr. Raquel Peyraube
Industry Advisor

Jorge Wernli
Industry Advisor

Prof. Dr. med Felix Gutzwiller
Industry Advisor

Dr. Gian Trepp
Industry Advisor

Dr. Isaac Kobrin is an internist with 15 years experience in the academic medicine both in Israel and the USA. He has over 22 years of experience in the Pharma Industry in Roche and Actelion. He has been responsible for the worldwide development of key compounds and has held numerous leadership positions in medical organisations.

Dr. Stéphane Redey has over 18 years experience leading teams in the technical development of innovative drugs and strategic outsourcing. He has held senior positions with global responsibilities in pharmaceutical companies in both Switzerland and Australia. He has led successful international collaborations with companies on four continents.

Dr. Raquel Peyraube is a specialist in the drug field with more than 28 years experience. Throughout her career she has been involved in training, prevention, treatment and harm reduction, developing innovative approaches emphasising ethical issues which has earned her international recognition. Dr Peyraube is currently a consultant on drug policy reform in Latin America.

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.

Felix Gutzwiller holds the titles of MD of the University of Basel, an MPH of the Harvard School of Public Health, Dr. PH of the Johns Hopkins University School of Hygiene and Public Health. He was a Professor at the University of Basel and a Professor of Social and Preventive Medicine at the University of Zürich (1988-2013), Emeritus since 2013.

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.
Why Cannabis?
Safety, Efficacy and Track Record

*Cannabis and Hemp extracts are remarkably safe and often the most effective (and sometimes only) treatment for some medical conditions.*

- **Long history of medicinal use, dating back thousands of years in many cultures**
- **Consists of over 460 compounds – at least 80 are active chemical compounds (Cannabinoids)**

Historically proven

Compound rich
Cannabidiol (CBD)

CBD is the second-most prominent compound found in the Cannabis Sativa plant, after THC and is **non-psychoactive**

CANNABIS/HEMP

- THC
  - Tetrahydrocannabinol
  - Psychoactive
- CBD
  - Cannabidiol
  - Non-Psychoactive
- Over 80 Other compounds

Preliminary studies have shown potential **therapeutic benefit** for CBD on various medical conditions

CBD’s **therapeutic value** comes from maintaining homeostasis by regulating, optimising and restoring the balance of key bodily systems (e.g. immune and metabolic systems)
Benefits of CBD

CBD has therapeutic value for many diseases and conditions

1. Therapeutic benefits
   - Anti-inflammatory
   - Anti-convulsant
   - Anti-oxidant
   - Anti-emetic
   - Anxiolytic
   - Anti-psychotic

2. Potential treatment of:
   - Anxiety/Stress Disorders
   - Metabolic Disorders/Diabetes
   - Neuro inflammation
   - Neurological Disorders/Epilepsy
   - Oxidative injury
   - Nausea
   - Schizophrenia

3. For pets:
   - Animal studies and extensive in vitro research suggest that CBD may have anti-inflammatory effects, may stimulate and regulate appetite, and may modulate anxiety and pain – without psychoactive effects
Vast Market Potential
Large and Rapidly Growing Markets

- **Global**: A $1.8 billion per-year industry, with sales now exceeding $4.5 billion
- **US**: A 3 million-patient market opportunity (More than 700K patients have already been prescribed)
- **Canada**: Estimated at $144 million in 2014, rising to $380 million by 2018, to $1.3 billion in the next 10 years
- **Europe**: Vast unmet demand. Small quantities usually imported from Holland's only national medical-grade cannabis (MGC) program supplier - Bedrocan.

### U.S. Marijuana Sales Estimates

<table>
<thead>
<tr>
<th>Year</th>
<th>Medical Marijuana</th>
<th>Recreational Marijuana</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>1.50</td>
<td>0</td>
</tr>
<tr>
<td>2014</td>
<td>1.75</td>
<td>0.65</td>
</tr>
<tr>
<td>2015</td>
<td>2.10</td>
<td>1.30</td>
</tr>
<tr>
<td>2016</td>
<td>2.70</td>
<td>1.90</td>
</tr>
<tr>
<td>2017</td>
<td>3.35</td>
<td>2.40</td>
</tr>
<tr>
<td>2018</td>
<td>3.80</td>
<td>4.00</td>
</tr>
</tbody>
</table>

### Market Size

<table>
<thead>
<tr>
<th>Country</th>
<th>Market Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>$6.4B</td>
</tr>
<tr>
<td>Canada</td>
<td>$0.18B</td>
</tr>
<tr>
<td>Europe</td>
<td>$7.53B</td>
</tr>
<tr>
<td>Australia (Est.)</td>
<td>$0.150B</td>
</tr>
</tbody>
</table>

1. Medical cannabis is a rapidly growing market. MMJ Business Daily. 2013.
Room to Grow

*Companies operating in the medical cannabis industry have seen significant growth*

- Bloomberg Intelligence\(^1\) has identified **55 public companies** whose business is based largely or completely on legal marijuana
- Top performers are providing a **stock return of >1000%**
- The 55 companies have a combined **market capitalisation of US$3 billion**

- **Viridian Cannabis Index Gained 38.4% in 2014**\(^2\)**
- Cannabis index outperformed all other indices in 2013, 2014 and Q1‘2015**\(^3\)**
- Three sectors continue to out-perform**\(^4\)**
  - Cultivation and Retail
  - Infused Products
  - Biotech

---

Filling an Unmet Need in the Market

The market for nutraceutical cannabinoids is still untapped

1. Generally, no GMP-certified production to produce standardized high-grade plant extracts

2. Lack of efficacious delivery systems to ensure sufficiently high bioavailability

3. Lack of seasoned and experienced pharmaceutical executives
Growth in Human Health Markets

Nutraceuticals are a multi-billion dollar industry
- Total global nutraceuticals market reached $142.1 billion in 2011
- Expected to reach $204.8 billion by 2017
- The nutraceutical ingredient market is forecast to reach $33.6 billion by 2018
- The overall US nutrition market was estimated at $137.4 billion in 2012, with supplements accounting for $32.4 billion

Multiple drivers for continued growth
- Rising health concerns, the growth of key demographics and growing consumer desire to lead a healthy life and avoid dependence on synthetic drugs are identified trends that show no sign of slowing down

Extremely lucrative for food and beverage companies
- Comparatively high margins
- Minimal regulatory requirements
- Germany, Switzerland, Netherlands, and Sweden have emerged as the key nutraceutical innovation hubs in Europe
Growth in Animal Health Markets

The Veterinary Nutraceutical Segment is very promising

- The recession-resistant animal health products industry is projected to continue showing rapid growth
- One of the biggest challenges of pet ownership is maintaining pets health
- 41% of pet owners have considered or tried various alternative therapies including:
  - Nutritional supplements (29%)
  - Herbal remedies (7%)
  - Homeopathy (4%)

**Metabolic Diseases**

**Our Primary Target Areas**

**Behavioral-based disorders:** anxiety, aggression, noise phobias

**Pain Relief**
The Creso Advantage
Creso’s subsidiary Hemp-Industries has a distribution agreement for its CBDium (cannabis oil) product.

Initial order for 10,000 bottles worth €195,000 with more orders expected to maintain constant supply.

CBDium will be supplied to hospitals and pharmacies.

Hemp-Industries owns hemp growing operations and has been running for three years.
Entourage Effect

- Creso only uses full plant extracts as opposed to synthetic or single molecule CBD rival products
- Cannabis is a poly molecule plant
- Full plant extracts contain other natural compounds in addition to CBD
- Research by Israeli scientists Shimon Ben-Shabat and Raphael Mechoulam show that cannabinoids and other compounds have a greater effect when taken together than when separated into individual compounds¹
- Many of these compounds interact synergistically to create the “Entourage Effect”

¹ http://www.academia.edu/4810567/An_entourage_effect_inactive_endogenous_fatty_acid_glycerol_esters_enhance_2-arachidonoyl-glycerol_cannabinoid_activity
Benefits of Full Plant Extracts

- Ability to affect multiple targets within the body
- Ability to improve the absorption of active ingredients
  - Cannabinoids are chemically polar compounds, which makes them more difficult to absorb in isolation
  - With the assistance of terpinoids like caryophyllene, absorption of cannabinoids is greatly increased
- Ability to overcome bacterial defense mechanisms
  - The full plant extracts also contains non-cannabinoid molecules with anti bacterian properties
  - These molecules attack bacteria through pathways which differ from cannabinoid pathways
  - Given the attack on multiple fronts, it is therefore possible to limit the development of bacterial resistance
- Ability to minimize adverse side effects
  - Certain cannabinoids modulate the negative side effects of others: for example CBD is able to modulate the psychoactive effects of THC
Improved Drug Absorption

• Creso’s products are designed for more effective delivery of dosage
• Delivery system is through buccal absorption (through the inside of the cheek)
• Drugs that are diffused into the blood through tissue will result in superior absorption than if it was swallowed
• Buccal mucosa has large surface area that provides direct access to a rich network of blood vessels (rich blood supply), offering the potential for rapid absorption of medications into the circulatory system.
# Unique Delivery Technologies

*Creso has exclusive world-wide use of two delivery technologies for cannabis treatments through licensing deals with pharma*

<table>
<thead>
<tr>
<th>INNutri Soft Gums™</th>
<th>BioLingus™ (Sublingual Tablets)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative soft chewable gums with a fillable center made of starch (not from animal material such as gelatin like other gums).</td>
<td>Novel proprietary platform for sublingual delivery of bio-active molecules for chronic diseases and immune-therapies.</td>
</tr>
<tr>
<td>✓ Easy to ingest</td>
<td>✓ Optimised and stable pill</td>
</tr>
<tr>
<td>✓ 60% cheaper than the gelatin capsules</td>
<td>✓ Robust manufacturing process</td>
</tr>
<tr>
<td>✓ Choice of flavours</td>
<td>✓ Similar efficiency to subcutaneous injection in mice</td>
</tr>
<tr>
<td>✓ Have non-sticky texture compared to other vegetarian products (starch, pectin)</td>
<td>✓ Highly scalable production process</td>
</tr>
<tr>
<td>✓ Vegan, Halal and Kosher</td>
<td>✓ Relatively low cost</td>
</tr>
<tr>
<td>✓ Suited for geriatric and pediatric use</td>
<td>✓ Long shelf life</td>
</tr>
<tr>
<td>✓ Heat resistant technology</td>
<td></td>
</tr>
<tr>
<td>✓ Gluten and Lactose free</td>
<td></td>
</tr>
</tbody>
</table>
Animal Health Nutraceutical Products

Creso has two animal health nutraceutical products for companion animals. EU approved, launch July 2017

1. One product is for horses which mainly targets stress symptoms, chronic joint pain and arthritis.

2. Second product is for dogs which mainly targets behavioural problems and pain and elderly dogs with chronic joint pain and arthritis.
Nutraceutical Products for Human and Animal Health

**Products based on Domaco buccal technology**

- Creso has signed an LOI for development, manufacturing and commercialisation of nutraceutical products in innovative delivery systems
- The new delivery systems are in line with Creso’s strategic approach for innovative buccal delivery systems with standardised dose and formulation
- Two new second-generation human health products: one for anxiety/stress (planned launch 1H2018) and one for bone metabolism (planned launch 1H2019)
- Products focused on fast onset of action (see Pipeline)
- One new animal health nutraceutical product for companion animals for behavioural disorders and pain (planned launch 1H2018)
Product Pipeline

Animal Health
- Ani-BiDiol 1 (CPH-3)
  Companion Animals/Horses
- Ani-BiDiol 2 (CPH-4)
  Companion Animals/dogs
- CPH-5 (Domaco)
  Companion Animals/Horses & Dogs

Human Health
- CannaQix (CPH-1A)
- CPH-1B (Domaco)
  Anxiety / Stress
- CPH-2 (Domaco)
  Bone Metabolism

* PPS = Prairie Plant Systems Canada

For personal use only

CBD-rich Nutraceuticals

Medical Cannabis Products

Ready for launch
Launch
Peer Comparison

_Creso is attractively priced relative to its peer group ($A)*_

<table>
<thead>
<tr>
<th>Feature</th>
<th>Creso</th>
<th>Auscann</th>
<th>Botanix</th>
<th>Medlab Clinical</th>
<th>MGC Pharmaceuticals</th>
<th>MMJ Phyotech</th>
<th>Zelda Therapeutics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Share price</td>
<td>54c</td>
<td>69.5c</td>
<td>4.9c</td>
<td>83.5c</td>
<td>6.7c</td>
<td>39c</td>
<td>6.2c</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$22.8m</td>
<td>$73.2m</td>
<td>$12.4m</td>
<td>$81.9m</td>
<td>$57.3m</td>
<td>$74.6m</td>
<td>$20.0m</td>
</tr>
<tr>
<td>GMP standard</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Natural botanical extracts / non synthetics</td>
<td>●</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Delivery technologies for better absorption</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Standardised dose &amp; formulation</td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Human &amp; animal health products</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Team with strong pharma &amp; cannabis record</td>
<td>●</td>
<td>●</td>
<td></td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Broad reach through nutraceutical market</td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
<td></td>
<td></td>
<td>●</td>
</tr>
</tbody>
</table>

*Data as at March 9, 2017.
Growing Investor Interest

*Investment has seen massive growth in 2015*, this trend is expected to continue<sup>2,3,4</sup>

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>Q1 2015</th>
<th>Q2 2015</th>
<th>Q3 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Companies</strong></td>
<td>31</td>
<td>24</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td><strong>Capital Raises</strong></td>
<td>47</td>
<td>42</td>
<td>41</td>
<td>21</td>
</tr>
<tr>
<td><strong>Total Funds</strong></td>
<td>$80.4M</td>
<td>$43.2M</td>
<td>$230.2M</td>
<td>$70.5M</td>
</tr>
<tr>
<td><strong>Top Three Sectors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consulting Services</td>
<td>$20.1M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AgTech</td>
<td>$15.9M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioTech</td>
<td>$208.4M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consumption Devices</td>
<td>$42.0M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cultivation and Retail</td>
<td>$18.9M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cultivation and Retail</td>
<td>$11.0M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Software</td>
<td>$6.6M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AgTech</td>
<td>$12.9M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotech</td>
<td>$12.3M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotech</td>
<td>$7.1M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consulting Services</td>
<td>$4.7M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotech</td>
<td>$5.5M</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The Strategy
Nutraceutical Strategy

Hemp based full-plant medical grade CBD-rich nutraceutical products which are efficacious, safe, standardised in composition and dose

A nutraceutical approach for both human and vet markets

1. **GMP sourcing only**: nutraceutical products from GMP-certified plants located in Europe, syndicated to our needs

2. **Standardized extraction**: GMP- and/or ISO-compliant extraction processes, to supply products of excellent quality, purity, and safety

3. **Owning and developing unique delivery methods**: source and license innovative and proven delivery platforms including tablets and sublinguals to increase absorption and bioavailability

4. **Sales channels**: Will not be sold online but will be registered with health authorities with full registration files

5. **Clinical trials**: perform small-scale clinical trials to gain scientific data

6. **IP**: Secure IP across the value chain
Hemp-Industries

**Hemp-Industries is the existing revenue generating division of Creso Pharma Limited**

- Hemp-Industries has been in operation and generating revenue for more than three years and operates an existing hemp growing operation in Slovakia as well as outsourced CBD extraction and CBD product sales activities.
- It is experiencing strong demand for its hemp seed products to feed consumer demand for “superfood”.
- In December, fulfilled second shipment of hemp protein to one of the largest bakeries in Slovakia, Pekárne Liptovský Hrádok, s.r.o. (PLH). HI’s protein is used by PLH to produce several top-quality protein bar products which are sold in leading grocery chains.
Hemp-Industries currently sells its CBDium products to the European market. Creso Pharma will seek to expand into other markets where CBD products have been legalised.

**Grow operations**
- Hemp-Industries grows industrial hemp in Slovakia
- Hemp is grown in certified organic fields
- Once grown, the hemp flowers are harvested and dried using specialised machinery
- Dried hemp is vacuum packaged in smaller bags for transport

**Extraction**
- Harvested and dried flowers are transferred to Hemp M&S OG (which is a separate company due to Slovak legislation)
- Flowers are separated from then remaining seeds and extracted with the use of CO2 fluid extraction
- Extract in its most natural form is then mixed with organic quality food oil to make it more pleasant in taste

**Final products**
- The final product is then tested for potency and food quality
- Products are then bottled, labelled and ready for sale in a direct marketing form or through distributors
- Two products currently available they are:
  - CBDium drops – 5% CBD >0.19%THC
  - CBDium drops – 3.1% and 1.9%CBDa 0.19%THC
Hemp-Industries Products in Pipeline

Hemp-Industries has over a dozen products in the pipeline

Hemp-Industries intends to manufacture over a dozen different products for sale complementing their existing revenue generating products below

Current products include:

- Hemp Seed Oil; and
- CBDium drops
Business Model

Research & Development

- **Delivery Technology Platforms**: Developing innovative technologies to deliver efficient, safe, quality and standardised doses of CBD and other phyto nutrients.
- **Agronomic & Botanic**: Developing the next generation of exceptional, high CBD yielding, non-GMO strains of cannabis.
- **Medical & Scientific**: Conducting well designed, controlled and small scale clinical trials in collaboration with research hospitals and centres.

Generate valuable **Intellectual Property (IP)**

Refinement & Commercialisation

- **Optimising and standardising extraction and production methods to Good Manufacturing Practice (GMP) standards.**

Develop a robust, valuable and marketable product
Intellectual Property (IP)

IP is the key to maximising value creation for any bio-pharmaceutical company. Creso’s work will conform with the expectations of the regulators and the bio-pharmaceutical sector.

Creso’s IP Strategy

A long term strategy incorporating global industry-wide reviews helping to identify areas of interest and opportunities - e.g., licensing agreements and royalty arrangements.

The IP portfolio will be related to Creso’s line of activity:
- Creso’s formulations
- Creso’s delivery platforms
- Therapeutic uses of cannabis/hemp derived compounds
- Know-how and trade secrets

IP Strategy Success

Creso’s success will depend on the ability to:
- Protect the proprietary rights of Creso’s prospect products, technology and know-how from others
- Operate without infringing on proprietary rights of others
Next 12 Months

Q2CY2017

- Sign development and commercialisation agreement with leading North American biopharmaceutical company

Q3CY2017

- Launch of first animal health product for horses
- Launch of first animal health product for dogs

CY2018

- Launch of first-generation human health nutraceutical product for anxiety and stress based on INNutri technology
- Launch of second-generation human health nutraceutical product for anxiety and stress based on Domaco buccal technology
- Launch of animal health product for horses and dogs based on Domaco technology
Investment Summary

**Rapidly Growing Markets**
• Increasing scientific evidence on efficacy of cannabis-based treatments
• Existing markets are expanding and new markets opening
• More countries are liberalising medicinal cannabis

**Strongly Performing Sector**
• Investor interest in sector is strong
• 50+ companies with business based largely on legal marijuana
• Industry in infancy with plenty of room to grow

**“Gold Standard”**
• Creso brings pharmaceutical industry rigour and professionalism to medicinal cannabis market
• Well placed to be the “Gold Standard” of the medicinal cannabis world

**Sound Business Model**
• Already revenue generating
• Diversified revenue streams from human and pet health markets
• Best practice for CBD extraction and drug delivery
• Resources in place for global sales

**Increased Consumer Demand**

**Strong Sales Revenue**

**Industry Leadership**

**Strong Company Returns**
Contact Information

For more information please contact:

**Creso Pharma Limited**

t: +61 8 6381 0054  
a: Level 4, 11 Ventnor Avenue  
West Perth WA Australia

**Mirador Corporate**  
Company Secretary  
t: +61 8 6381 0054  
a: Level 4, 11 Ventnor Avenue  
West Perth WA Australia

**EverBlu Capital**  
Corporate Advisor  
t: 02 8249 0000  
e: info@everblucapital.com  
w: www.everblucapital.com  
a: Level 39, Aurora Place,  
88 Phillip Street,  
Sydney NSW Australia